Model: Anti-tumor efficacy

Models (Disease)

Pharmacology (Safety)

Anti-tumor efficacy models evaluate the therapeutic efficacy of a specific therapy using human xenograft or murine syngeneic animal models. These models can be used to advance preclinical drug development efforts. For example, a murine model of subcutaneous colorectal adenocarcinoma (CT26) was used to assess the impact of checkpoint blockade by anti-mPD-1, anti-mPD-L1 or anti-mCTLA-4 on established disease. These regimens were moderately responsive, enabling these data to inform downstream rational combination strategies with these agents.

Human and murine tumor models can be used to assess subcutaneous, orthotopic, systemic, and/or metastatic disease and the impact of treatment on disease progression.

Molecule or Product Type

Biologics, Small Molecule

Models

Human, Mouse

Administration Routes

Dermal, Dietary, Gavage, Implant, Intramuscular, Intraperitoneal, Intravenous, Subcutaneous

Regulatory

FIH, IND & CTA

Industry Market

Pharma

Phase

Discovery

Request a Quote

About our nonclinical animal research models: We provide the utmost care for our research animals and actively pursue advances in animal welfare. As well as ensuring the highest scientific, ethical and regulatory standards, selection of appropriate animal research models for development research is critical to developing safe and effective treatments, devices and products that protect and save lives. Just as we have ethical committee oversight for human trials, we have ethical committees overseeing all aspects of our global animal care and use programs. All of our core, nonclinical facilities are accredited by AAALAC. Learn more about our commitment to replacing, reusing and refining nonclinical research models.